How much Celltrion’s ‘Remsima’ is prescribed in Europe?
It was observed the collective number of patients prescribed for the Celltrion’s autoimmune disease treatment ‘Remsima(U.S. Johnson & Johnson’s ‘Remicade’ biosimilar)’ is about 100 thousand, accounting for approximately 40% of the European infliximab(substance of ‘Remicade’) market.
By country,...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
